Hologic debuts pooling protocol for COVID-19 tests

By LabPulse.com staff writers

August 11, 2020 -- Hologic has validated the use of its Aptima and Panther Fusion molecular diagnostic COVID-19 assays with pooled patient samples and has also applied for an emergency use authorization (EUA) to the U.S. Food and Drug Administration for pooled test processing.

Pooled workflow allows clinical laboratories to combine up to five COVID-19 patient samples into a single tube for processing. It would be available to Hologic's laboratory customers in the U.S. if granted the EUA.

Pooling enables more samples to be tested simultaneously, which would help labs increase the number of test results they deliver more quickly.

Molecular diagnostics sales surge in Hologic's Q3
A strong surge in sales of its molecular diagnostics products helped Hologic offset declines in other areas of the company's business in its third fiscal...
FDA gives Hologic EUA for SARS-CoV-2 test
The U.S. Food and Drug Administration (FDA) gave Hologic emergency use authorization (EUA) for its Aptima SARS-CoV-2 molecular test for detection of the...
Hologic debuts research-use-only SARS-CoV-2 test
Hologic has launched a research-use-only version of a new molecular assay that can detect SARS-CoV-2 and which is expected to dramatically increase testing...
Hologic molecular test helps Quest avoid coronavirus backlog
Thanks in part to the use of a molecular test from Hologic, Quest Diagnostics has reported another increase in the volume of novel coronavirus diagnostics...
Hologic secures emergency authorization for COVID-19 test
Medical technology company Hologic has garnered U.S. Food and Drug Administration emergency use authorization for its Panther Fusion SARS-CoV-2 molecular...

Copyright © 2020 LabPulse.com

Last Updated ls 8/11/2020 4:12:38 PM



Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email
Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current